GeoVax Labs, Inc.
1900 Lake Park Drive, Suite 380
Smyrna, GA 30080

You Might Also Like...

Key Points About GeoVax

Recent News Releases

GeoVax Labs, Inc. (GOVX-NASDAQ)

GeoVax Labs, Inc. (“GeoVax” or “the Company”) is a clinical-stage biotechnology company developing preventive and therapeutic human vaccines against infectious diseases and cancer. The Company’s proprietary GV-MVA-VLP™ vector vaccine technology utilizes a Modified Vaccinia Ankara (MVA) vector, a large virus capable of carrying several vaccine antigens, that are expressed as non-infectious virus-like particles (VLPs) in the individual receiving the vaccine (in vivo). VLPs mimic a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection through durable immune responses. GeoVax is capitalizing on the safety and efficacy of its technology platform to address the urgent need for a COVID-19 vaccine and is also developing vaccines against human immunodeficiency virus (HIV), Zika virus (ZIKV), hemorrhagic fever (HF) viruses (Ebola, Sudan, Marburg, and Lassa Fever) and malaria. Furthermore, the Company is applying its MVA-VLP technology to cancer immunotherapy (immuno-oncology).

* The Corporate Snapshot was last updated on September 21, 2020.


Latest Research




Download GeoVax Labs, Inc.  Updated Base Report 10-21-2020




Past Research


NEW UPDATE! 05-11-21



Download Update 03-29-21 



Download Update 02-16-21



Download Update 11-11-20


Cover Image Update 05-28-19

Download Update 05-28-19

Cover Image Update 04-01-19

Download Update 04-01-2019

Cover Image Update 11-14-18

 Download Update 11-14-2018

Cover Image Update 08-14-18_jpg

Download Update   08-14-2018


Download Update 03-01-2018


Download Update 10-18-2017


Download GeoVax Report 06-15-2017

Key Points About GeoVax

Blogs: GOVX